

**1. DESCRIPTION****1.1. Therapeutic / Pharmacologic Class of Drug**

ATC Code: N04BA02

Madopar is a combination of levodopa and the decarboxylase inhibitor benserazide.

1.2. Type of Dosage Form*Standard forms:*

Capsules as Madopar ‘125’

Cross-scored tablets as Madopar ‘250’

Dispersible form:

Single-scored dispersible tablets as Madopar ‘125’

Controlled release forms:

Capsules (Hydrodynamically Balanced System (HBS)) as Madopar ‘125’

Not all strengths are available.

1.3. Route of Administration

Oral.

1.4. Composition*Active ingredients:*

Madopar is a combination of levodopa and the decarboxylase inhibitor benserazide (as hydrochloride) in the ratio of 4:1. The following strengths are available:

- Madopar ‘125’ = levodopa 100 mg + benserazide 25 mg
- Madopar ‘250’ = levodopa 200 mg + benserazide 50 mg

Excipients:

Madopar contains the colorants indigotine (E 132), titanium dioxide (E 171) or iron oxide (E 172) depending on the formulation.

The preparation is available as capsules, cross-scored tablets, dispersible tablets and capsules with a controlled-release action:

Madopar ‘125’ (blue and pink capsules) with 100 mg levodopa + 25 mg benserazide (as hydrochloride);

Madopar ‘250’ cross scored (pink tablets) with 200 mg levodopa + 50 mg benserazide (as hydrochloride);

Madopar ‘dispersible 125’ scored (off-white tablets) with 100 mg levodopa + 25 mg benserazide (as hydrochloride);

Madopar HBS (Hydrodynamically Balanced System) (controlled-release green and light blue capsules) with 100 mg levodopa + 25 mg benserazide (as hydrochloride).

Madopar HBS capsules must not be opened or chewed before swallowing because the controlled-release characteristics will be lost!

2. CLINICAL PARTICULARS**2.1. Therapeutic Indications***Parkinson’s disease:*

Madopar is indicated for the treatment of Parkinson’s disease with the exception of drug-induced Parkinsonism.

Madopar dispersible is a formulation which is suitable for patients with dysphagia (difficulties in swallowing) or who require a formulation with a more rapid onset of action, e.g. patients suffering from early morning and afternoon akinesia, or who exhibit ‘delayed on’ or ‘wearing off’ phenomenon.

Madopar HBS is indicated for patients presenting with all types of fluctuations (i.e. ‘peak dose dyskinesia’ and ‘end of dose deterioration’ – such as nocturnal immobility).

2.2. Dosage and Administration*Method of administration*

When taking standard Madopar capsules or Madopar HBS, patients must always ensure that they swallow the whole capsule without chewing it.

Standard Madopar tablets are breakable to facilitate swallowing.

Madopar dispersible tablets are to be dispersed in a quarter of a glass of water (approx. 25-50 ml). The tablets disintegrate completely, producing a milky-white dispersion within a few minutes. Because of rapid sedimentation, it is advisable to stir the dispersion before drinking. Madopar dispersible tablets should be taken within half an hour of preparing the dispersion.

Parkinson’s disease:

When possible, Madopar should be taken at least 30 minutes before or 1 hour after meals so that the competitive effect of dietary protein on levodopa uptake can be avoided (see section 2.8 Interactions with other Medicinal Products and other Forms of Interaction) and to facilitate a more rapid onset of action. Undesirable gastrointestinal effects, which may occur mainly in the early stages of the treatment, can largely be controlled by taking Madopar with a low protein snack [e.g. biscuits] or liquid or by increasing the dose slowly.

Standard dosage

Treatment with Madopar should be introduced gradually; dosage should be assessed individually and titrated for optimal effect. The following dosage instructions should therefore be regarded as guidelines.

Initial therapy

In the early stages of Parkinson’s disease it is advisable to start treatment with ½ tablet of Madopar ‘125’ three to four times daily. As soon as tolerability of the initial dosing schedule is confirmed, the dosage should be increased slowly in accordance with the patient’s response.

An optimal effect is generally achieved with a daily dosage of Madopar corresponding to 300-800 mg levodopa + 75-200 mg benserazide, to be divided into 3 or more doses. Between

4 and 6 weeks may be needed to achieve the optimal effect. If it proves necessary to further increase the daily dosage, this should be done on a monthly basis.

Maintenance therapy

The average maintenance dosage is 1 capsule or tablet of Madopar ‘125’ 3 to 6 times daily. The number of individual doses (not less than 3) and their distribution throughout the day must be titrated for optimal effect. Madopar HBS and Madopar dispersible may substitute standard Madopar to achieve an optimal effect.

2.2.1. Special dosage instructions*Renal Impairment:*

No dose reduction is considered necessary in case of mild or moderate renal insufficiency (see sections 2.3 Contraindications, 2.5.6 Renal Impairment).

Hepatic Impairment:

The safety and efficacy of Madopar have not been established in patients with hepatic impairment (see sections 2.3 Contraindications, 2.5.7 Hepatic Impairment).

Parkinson’s disease:

Dosage must be carefully titrated in all patients (see section 2.2 Dosage and Administration). Patients on other anti-parkinsonian agents may receive Madopar. However, as treatment with Madopar proceeds and the therapeutic effect becomes apparent, the dosage of the other drugs may need to be reduced or these drugs gradually withdrawn.

Madopar dispersible tablets are particularly suitable for patients with dysphagia (difficulties in swallowing) or in situations where a more rapid onset of action is required e.g. patients suffering from early morning and afternoon akinesia, or who exhibit ‘delayed on’ or ‘wearing off’ phenomenon.

Patients who experience large fluctuations in the drug’s effect in the course of the day (on-off phenomena) should receive smaller, more frequent single doses, or be switched to Madopar HBS.

The switch from standard Madopar to Madopar HBS is preferably made from one day to the next, beginning with the morning dose. The daily dose and dosing interval should initially be the same as with standard Madopar.

After 2-3 days, the dosage should be gradually increased by about 50%. Patients should be informed that their condition may temporarily deteriorate.

Due to the pharmacokinetic properties of Madopar HBS, the onset of action is delayed. The clinical effect may be achieved more rapidly by administering Madopar HBS together with standard Madopar or Madopar dispersible. This may prove especially useful for the first morning dose, which should preferably be higher than the subsequent daily doses. The individual titration for Madopar HBS must be carried out slowly and carefully, allowing intervals of at least 2-3 days between dose changes.

In patients with nocturnal immobility, positive effects have been reported after gradually increasing the last evening dose up to 250 mg of Madopar HBS on retiring.

Excessive responses to Madopar HBS (dyskinesia) can be controlled by increasing the interval between doses rather than by reducing the single doses.

Treatment with standard Madopar or Madopar dispersible should be resumed if the response to Madopar HBS is inadequate.

2.3. Contraindications

Madopar is contraindicated in:

- patients with known hypersensitivity to levodopa or benserazide or any of the excipients.
- patients receiving non-selective monoamine oxidase (MAO) inhibitors due to the risk of hypertensive crisis (see section 2.4.1 Warnings and Precautions, General). However, selective MAO-B inhibitors, such as selegiline and rasagiline or selective MAO-A inhibitors, such as moclobemide, are not contraindicated. Combination of MAO-A and MAO-B inhibitors is equivalent to non-selective MAO inhibition, and hence this combination should not be given concomitantly with Madopar (see section 2.8 Interactions with other Medicinal Products and other Forms of Interaction).
- patients with decompensated endocrine, renal or hepatic function, cardiac disorders, psychiatric diseases with a psychotic component or closed angle glaucoma.
- patients less than 25 years old (skeletal development must be complete).
- pregnant women or women of childbearing potential in the absence of adequate contraception (see 2.5.2 Pregnancy and 2.5.3 Lactation). If pregnancy occurs in a woman taking Madopar, the drug must be discontinued (as advised by the prescribing physician).

2.4. Warnings and Precautions**2.4.1. General***Warnings related to immunological reactions*

Hypersensitivity reactions may occur in susceptible individuals.

Warnings related to neurological and psychiatric effects

Madopar must not be withdrawn abruptly. Abrupt withdrawal of the preparation may result in a neuroleptic malignant-like syndrome (hyperpyrexia and muscular rigidity, possibly psychological changes and elevated serum creatinine phosphokinase) which may be life-threatening. Should a combination of such symptoms and signs occurs, the patient should be kept under medical surveillance, if necessary, hospitalized and rapid and appropriate symptomatic treatment given. This may include resumption of Madopar therapy after an appropriate evaluation.

Patients should be carefully observed for possible undesirable psychiatric symptoms.

Depression can be part of the clinical picture in patients with Parkinson’s disease and may also occur in patients treated with Madopar.

Levodopa has been associated with somnolence and episodes of sudden sleep onset. Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported very rarely. Patients must be informed of

this and advised to exercise caution while driving or operating machines during treatment with levodopa. Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines. Furthermore a reduction of dosage or termination of therapy may be considered (see section 2.4.3 Ability to Drive and Use Machines).

Dopaminergic drugs: Impulse control disorders such as pathological gambling, increased libido and hypersexuality have been reported in patients treated with dopamine agonists for Parkinson’s Disease. There is no established causal relationship between Madopar, which is not a dopamine agonist, and these events. However, caution is advised as Madopar is a dopaminergic drug.

Warnings related to ocular effects

Regular measurement of intraocular pressure is advisable in patients with open-angle glaucoma, as levodopa theoretically has the potential to raise intraocular pressure.

Warnings related to Interactions

If a patient on levodopa requires a general anaesthesia, the normal Madopar regimen should be continued as close to the surgery as possible, except in case of halothane. In general anaesthesia with halothane, Madopar should be discontinued 12-48 hours before surgical intervention as fluctuations in blood pressure and/or arrhythmias may occur in patients on Madopar therapy. Madopar therapy may be resumed following surgery; the dosage should be increased gradually to the preoperative level.

If Madopar is to be administered to patients receiving irreversible non-selective MAO inhibitors, an interval of at least 2 weeks should be allowed between cessation of the MAO inhibitor and the start of Madopar therapy. Otherwise unwanted effects such as hypertensive crisis are likely to occur (see sections 2.3 Contraindications and 2.8 Interactions with other Medicinal Products and other Forms of Interaction).

Concomitant administration of antipsychotics with dopamine-receptor blocking properties, particularly D2-receptor antagonists might antagonize the antiparkinsonian effects of levodopa-benserazide. Levodopa may reduce antipsychotic effects of these drugs. These drugs should be co-administered with caution (see section 2.8 Interactions with other Medicinal Products and other Forms of Interaction).

Madopar should not be administered concomitantly with sympathomimetics (such as epinephrine, norepinephrine, isoproterenol or amphetamine which stimulate the sympathetic nervous system) as levodopa may potentiate their effects. Should concomitant administration prove necessary, close surveillance of the cardiovascular system is essential, and the dose of the sympathomimetic agents may need to be reduced (see section 2.8 Interactions with other Medicinal Products and other Forms of Interaction).

When initiating an adjuvant treatment with a COMT inhibitor, a reduction of the dosage of Madopar may be necessary.

Anticholinergics should not be withdrawn abruptly when Madopar therapy is instituted, as levodopa does not begin to take effect for some time.

Combination with anticholinergics, amantadine, selegiline, bromocriptine and dopamine agonists is permissible, though both the desired and the undesired effects of treatment may be intensified. It may be necessary to reduce the dosage of Madopar or the other substance (see section 2.8 Interactions with other Medicinal Products and other Forms of Interaction).

Laboratory Tests

Checks of liver function and blood cell count should be performed during treatment (see section 2.6.1 Post Marketing Experience). Patients with diabetes should undergo frequent blood sugar tests, and the dosage of antidiabetic agents should be adjusted to blood sugar levels.

2.4.2. Drug Dependence and Abuse

Dopamine dysregulation syndrome (DDS): a small number of patients have been known to suffer from cognitive and behavioural disturbance that can be directly attributed to taking increasing quantities of medication against medical advice and well beyond the doses required to treat their motor disabilities.

2.4.3. Ability to Drive and Use Machines

Madopar may have a major influence on the ability to drive and use machines.

Patients being treated with levodopa and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death. (e.g. operating machines) until such recurrent episodes and somnolence have resolved (see section 2.4.1 General).

2.5. Use in Special Populations**2.5.1. Females and Males of Reproductive Potential***Fertility*

No fertility studies have been performed (see section 3.3 Nonclinical Safety).

Pregnancy testing

A pregnancy test prior to treatment is recommended to exclude pregnancy.

Contraception

Adequate contraception should be used in women of childbearing potential during treatment with Madopar.

2.5.2. Pregnancy

Madopar is contraindicated during pregnancy and in women of childbearing potential in the absence of adequate contraception (see sections 2.3 Contraindications, 3.3.4 Reproductive Toxicity and 3.3.5 Other).

If pregnancy occurs in a woman taking Madopar, the drug must be discontinued (as advised by the prescribing physician).

Labor and Delivery

The safe use of Madopar during labor and delivery has not been established.

2.5.3. Lactation

The safe use of Madopar during lactation has not been established.

It is not known whether benserazide is excreted in human breast milk. Mothers requiring Madopar treatment should not nurse their infants, as the occurrence of skeletal malformations in the infants cannot be excluded.

2.5.4. Pediatric Use

Madopar is contraindicated in patients less than 25 years old (see section 2.3 Contraindications).

2.5.5. Geriatric Use

See section 3.2.5 Pharmacokinetics in Special Populations.

2.5.6. Renal impairment

Levodopa and benserazide are both extensively metabolized and less than 10% of levodopa is excreted unchanged through the kidneys. It is unlikely that dose adjustments are necessary in mild or moderate renal insufficiency (see section 2.2.1 Special Dosage Instructions).

Pharmacokinetic data with levodopa in renal impaired patients are not available. Madopar must not be given to patients with decompensated renal function.

2.5.7. Hepatic impairment

Levodopa is mainly metabolized by the aromatic amino acid decarboxylase that is abundantly present in the intestinal tract, in kidney and heart in addition to the liver (see section 2.2.1 Special Dosage Instructions).

Pharmacokinetic data with levodopa in hepatic impaired patients are not available. Madopar must not be given to patients with decompensated hepatic function.

2.6. Undesirable effects**2.6.1. Post marketing Experience**

The following adverse reactions have been identified from post marketing experience with Madopar (Table 1) based on spontaneous case reports and literature cases.

The corresponding frequency category estimation for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (these reactions are reported voluntarily from a population of uncertain size, therefore it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure).

Table 1 Adverse Drug Reactions from post marketing experience

Adverse Drug Reactions	Frequency category
Blood and Lymphatic System Disorders¹:	
Haemolytic anaemia	Not known
Transient leukopenia	Not known
Thrombocytopenia	Not known
Metabolic and nutritional disorders:	
Anorexia	Not known
Psychiatric Disorders:	
Depression	Not known
Agitation	Not known
Anxiety	Not known
Insomnia	Not known
Hallucinations	Not known
Delusions	Not known
Temporal disorientation	Not known
Dopamine dysregulation syndrome (DDS)	Not known
Nervous System Disorder:	
Ageusia	Not known
Dysgeusia	Not known
Dyskinesia (choreiform and athetotic)	Not known
Fluctuations in therapeutic response	Not known
- Freezing episodes	
- end-of-dose deterioration	
- “on-off” effect	
Augmentation of RLS	Not known
Somnolence	Not known
Excessive daytime sleepiness	Not known
Sudden sleep onset episodes	Not known
Cardiac disorders:	
Cardiac arrhythmias	Not known
Vascular Disorders:	
Orthostatic hypotension	Not known
Gastrointestinal disorders:	
Nausea	Not known
Vomiting	Not known
Diarrhoea	Not known
Saliva discolouration	Not known
Tongue discolouration	Not known
Tooth discolouration	Not known
Oral mucosa discolouration	Not known
Skin and subcutaneous tissue disorders:	
Pruritus	Not known
Rash	Not known
Liver and Biliary disorders:	
Transaminases increased	Not known
Alkaline phosphatase increase	Not known
Gamma-glutamyltransferase increased	Not known
Renal and urinary disorders:	
Chromaturia	Not known
Blood urea nitrogen increased	Not known

¹See section 2.4.1 Warnings and Precautions, *Laboratory Tests*

Blood and Lymphatic System Disorders: Haemolytic anaemia, transient leukopenia and thrombocytopenia have been reported. In any long-term levodopa-containing treatment, blood cell count and liver and kidney function should be monitored periodically.

Psychiatric Disorders: Depression can be part of the clinical picture in patients with Parkinson’s disease and may also occur in patients treated with Madopar. Agitation, anxiety,

insomnia, hallucinations, delusions and temporal disorientation may occur particularly in elderly patients and in patients with a history of such disorders.

Nervous System Disorder: At later stages of the treatment, dyskinesia (e.g. choreiform or athetotic) may occur. These can usually be eliminated or be made tolerable by a reduction of dosage. With prolonged treatment, fluctuations in therapeutic response may also be encountered.

They include freezing episodes, end-of-dose deterioration and the “on-off” effect. These can usually be eliminated or made tolerable by adjusting the dosage and by giving smaller doses more frequently. An attempt at increasing the dosage again can subsequently be made in order to intensify the therapeutic effect. Madopar is associated with somnolence and has been associated very rarely with excessive daytime sleepiness and sudden sleep onset episodes.

Vascular Disorders: Orthostatic disorders commonly improve following reduction of the Madopar dosage.

Gastrointestinal disorders: Undesirable gastrointestinal effects, which may occur mainly in the early stages of the treatment, can largely be controlled by taking Madopar with a low protein snack or liquid or by increasing the dose slowly.

Investigations: Urine may be altered in colour, usually acquiring a red tinge which turns dark on standing. Other body fluids or tissues may also be discoloured or stained including saliva, the tongue, teeth or oral mucosa.

2.7. Overdose

Symptoms and signs

Symptoms and signs of overdose are qualitatively similar to the side effects of Madopar in therapeutic doses but may be of greater severity. Overdose may lead to: cardiovascular side effects (e.g. cardiac arrhythmias), psychiatric disturbances (e.g. confusion and insomnia), gastro-intestinal effects (e.g. nausea and vomiting) and abnormal involuntary movements (see section 2.6.1 Post marketing Experience (Undesirable Effects)).

If a patient has taken an overdose of a controlled release form of Madopar (i.e. Madopar HBS capsules), occurrence of symptoms and signs may be delayed due to delayed absorption of the active substances from the stomach.

Treatment

Monitor the patient’s vital signs and institute supportive measures as indicated by the patient’s clinical state. In particular patients may require symptomatic treatment for cardiovascular effects (e.g. antiarrhythmics) or central nervous system effects (e.g. respiratory stimulants, neuroleptics).

In addition, for the controlled release formulations further absorption should be prevented using an appropriate method.

2.8. Interactions with other Medicinal Products and other Forms of Interaction

Pharmacokinetic interactions

Coadministration of the anticholinergic drug trihexyphenidyl with standard Madopar reduces the rate, but not the extent, of levodopa absorption. Trihexyphenidyl given concomitantly with Madopar HBS does not affect the pharmacokinetic of levodopa.

Coadministration of antacids with Madopar HBS reduces the extent of levodopa absorption by 32%.

Ferrous sulphate decreases the maximum plasma concentration and the AUC of levodopa by 30-50%. The pharmacokinetic changes observed during co-treatment with ferrous sulphate appear to be clinically significant in some but not all patients.

Metoclopramide increases the rate of levodopa absorption.

Domperidone may increase the bioavailability of levodopa as a result of increased absorption of levodopa in the intestine.

Pharmacodynamic interactions

Neuroleptics, opioids and antihypertensive medications containing reserpine inhibit the action of Madopar.

If Madopar is to be administered to patients receiving irreversible non-selective MAO inhibitors, an interval of at least 2 weeks should be allowed between cessation of the MAO inhibitor and the start of Madopar therapy. Otherwise unwanted effects such as hypertensive crisis are likely to occur (see section 2.3 Contraindications). Selective MAO-B inhibitors, such as selegiline and rasagiline and selective MAO-A inhibitors, such as moclobemide, can be prescribed to patients on Madopar therapy; it is recommended to readjust the levodopa dose to the individual patient’s need, in terms of both efficacy and tolerability. Combination of MAO-A and MAO-B inhibitors is equivalent to non-selective MAO inhibition and hence this combination should not be given concomitantly with Madopar (see section 2.3 Contraindications).

Madopar should not be administered concomitantly with sympathomimetics (agents such as epinephrine, norepinephrine, isoproterenol or amphetamine which stimulate the sympathetic nervous system) as levodopa may potentiate their effects. Should concomitant administration prove necessary, close surveillance of the cardiovascular system is essential, and the dose of the sympathomimetic agents may need to be reduced.

Combination with anticholinergics, amantadine, selegiline, bromocriptine and dopamine agonists is permissible, though both the desired and the undesired effects of treatment may be intensified. It may be necessary to reduce the dosage of Madopar or the other substance.

When initiating an adjuvant treatment with a COMT inhibitor, a reduction of the dosage of Madopar may be necessary.

Anticholinergics should not be withdrawn abruptly when Madopar therapy is instituted, as levodopa does not begin to take effect for some time.

Concomitant administration of antipsychotics with dopamine-receptor blocking properties, particularly D2-receptor antagonists might antagonize the antiparkinsonian effects of levodopa-benserazide. Levodopa may reduce antipsychotic effects of these drugs. These drugs should be co-administered with caution.

General anaesthesia with halothane: Madopar should be discontinued 12 – 48 hours before surgical intervention requiring general anaesthesia with halothane as fluctuations in blood pressure and/or arrhythmias may occur.

For general anesthesia with other anaesthetics see section 2.4.1 General (Warnings and Precautions).

Laboratory test interactions

Levodopa may affect the results of laboratory test for catecholamines, creatinine, uric acid and glycosuria. The urine test results can be false positive for ketone bodies.

Coombs’ tests may give a false-positive result in patients taking Madopar.

Food interactions

A diminution of effect is observed when the drug is taken with a protein-rich meal.

Levodopa is a large neutral amino acid (LNAA) and it competes with LNAAs from dietary protein for transport across the gastric mucosa and blood-brain barrier.

3. PHARMACOLOGICAL PROPERTIES AND EFFECTS

3.1. Pharmacodynamic Properties

3.1.1. Mechanism of Action

Parkinson’s disease

Dopamine, which acts as a neurotransmitter in the brain, is not present in sufficient quantities in the basal ganglia of parkinsonian patients. Levodopa (INN) or L-DOPA (3,4-dihydroxy L-phenylalanine) is an intermediate in dopamine biosynthesis. Levodopa (dopamine precursor) is used as a prodrug to increase dopamine levels since it is able to cross the blood-brain barrier whereas dopamine itself cannot. Once levodopa has entered the central nervous system (CNS), it is metabolized to dopamine by aromatic L-amino acid decarboxylase.

After administration, levodopa is rapidly decarboxylated to dopamine, in extracerebral as well as cerebral tissues. As a result, most of the levodopa administered is not available to the basal ganglia, and the dopamine produced peripherally frequently causes unwanted effects. It is therefore particularly desirable to inhibit extracerebral decarboxylation of levodopa. This can be achieved by simultaneous administration of levodopa and benserazide, a peripheral decarboxylase inhibitor.

Madopar is a combination of these two substances in a ratio 4:1 – this ratio having proved optimal in clinical trials and therapeutic use – and is just as effective as large doses of levodopa given alone.

3.2. Pharmacokinetics Properties

3.2.1. Absorption

Standard forms

Levodopa is mainly absorbed from the upper regions of the small intestine, and absorption there is independent of the site. Maximum plasma concentrations of levodopa are reached approximately one hour after ingestion of standard Madopar.

Capsules and tablets of standard Madopar are bioequivalent.

The maximum plasma concentration of levodopa and the extent of levodopa absorption (AUC) increase proportionately with dose (50-200 mg levodopa).

Food intake reduces the rate and extent of levodopa absorption. The peak levodopa plasma concentration is 30% lower and occurs later when standard Madopar is administered after a standard meal. The extent of levodopa absorption is reduced by 15%.

Dispersible form

The pharmacokinetic profiles of levodopa following administration of Madopar dispersible in healthy volunteers and parkinsonian patients are very similar to those following administration of standard Madopar, but time to peak concentrations tends to be shorter after Madopar dispersible. There is less interindividual variability in absorption parameters for Madopar dispersible taken as a suspension.

Controlled release form

The pharmacokinetic properties of Madopar HBS differ from those of standard Madopar (capsules, tablets) and dispersible form. The active ingredients are released slowly in the stomach. Maximum plasma concentrations of levodopa, which are 20-30% of those achieved with the standard dosage forms, are reached about 3 hours after administration. The plasma concentration-time curve shows a longer ‘half-value duration’ (time span during which plasma concentrations are equal to or exceed half the maximum concentration) than with standard Madopar, which indicates pronounced controlled-release properties. The bioavailability of Madopar HBS is 50-70% of that of standard Madopar and is not affected by food. Maximum plasma concentrations of levodopa are not affected by food, but occur later (5hours) after post-prandial administration of Madopar HBS.

3.2.2. Distribution

Levodopa crosses the gastric mucosa and the blood-brain barrier by a saturable transport system. It is not bound to plasma proteins and its volume of distribution is 57 liters. The AUC of levodopa in cerebrospinal fluid is 12% of that in plasma.

In contrast to levodopa, benserazide does not penetrate the blood-brain barrier at therapeutic doses. It is concentrated mainly in the kidneys, lungs, small intestine and liver.

3.2.3. Metabolism

Levodopa is metabolized by two major pathways (decarboxylation and O-methylation) and two minor ones (transamination and oxidation).

Aromatic amino acid decarboxylase converts levodopa to dopamine. The major end-products of this pathway are homovanillic acid and dihydroxyphenylacetic acid. Catechol-O-methyltransferase methylates levodopa to 3-O-methyldopa. This major plasma metabolite has an elimination half-life of 15 hours and it accumulates in patients who receive therapeutic doses of Madopar.

Decreased peripheral decarboxylation of levodopa when it is administered with benserazide is reflected in higher plasma levels of levodopa and 3-O-methyldopa and lower plasma levels of catecholamines (dopamine, noradrenaline) and

phenolcarboxylic acids (homovanillic acids, dihydroxyphenylacetic acid).

Benserazide is hydroxylated into trihydroxybenzylhydrazine in the intestinal mucosa and the liver. This metabolite is a potent inhibitor of the aromatic amino acid decarboxylase.

3.2.4. Elimination

In the presence of peripherally inhibited levodopa decarboxylase the elimination half-life of levodopa is approximately 1.5 hours. The elimination half-life is slightly longer (approximately 25%) in geriatric patients (65-78 years of age) with Parkinson’s disease (see section 3.2.5 Pharmacokinetic in Special Population). The clearance of levodopa from plasma is about 430 ml/min.

Benserazide is almost entirely eliminated by metabolism. The metabolites are mainly excreted in the urine (64%) and to a smaller extent in feces (24%).

3.2.5. Pharmacokinetics in Special Populations

No pharmacokinetic data are available in uremic and hepatic patients.

Effect of age on the pharmacokinetics of levodopa

In older Parkinsonian patients (65 – 78 years of age) both the elimination half-life and the AUC of levodopa is about 25% higher than in younger patients (34 – 64 years of age). The statistically significant age effect is clinically negligible and is of minor importance for the dosing schedule of any indication.

3.3. Nonclinical Safety

3.3.1. Carcinogenicity

No carcinogenicity studies have been performed to establish the carcinogenic potential of Madopar.

3.3.2. Mutagenicity

Madopar and its constituents (levodopa and benserazide) were not observed to be mutagenic in the Ames test. No further data are available.

3.3.3. Impairment of Fertility

No fertility studies on animals have been performed to evaluate the effect of Madopar.

3.3.4. Reproductive toxicity

Animal studies have shown the possibility of disturbed fetal skeletal development.

General toxicity studies with benserazide in adult rats have shown the possibility of an interference with the epiphyses (growth plates) of bones. The skeletal growth plates of humans close at around the time of puberty, whilst those of rodents remain active into adulthood. There is thus a theoretical risk of disturbed fetal skeletal growth in the human child.

Teratogenicity studies showed no dysmorphic effects or effects on pre-natal skeletal development in mice (400 mg/kg) and rats (600 mg/kg; 250 mg/kg).

At maternally toxic dose levels, intrauterine deaths increased (rabbits) and/or fetal weight decreased (rats).

3.3.5. Other

General toxicological studies in rats have shown the possibility of disturbed skeletal development.

4. PHARMACEUTICAL PARTICULARS

4.1. Storage

The medicine should not be used after the expiry date (EXP) shown on the pack. See also outer pack for storage remark.

Madopar should be stored in its original package.

The bottle should be kept tightly closed, to protect from moisture.

4.2. Special Instruction for Use, Handling and Disposal

The release of pharmaceuticals in the environment should be minimized. Medicines should not be disposed of via wastewater and disposal through household waste should be avoided.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

5. PACKS

Madopar ‘125’ Capsules with 100 mg levodopa + 25 mg benserazide	100
Madopar ‘250’ Tablets (cross-scored) with 200 mg levodopa + 50 mg benserazide	100
Madopar ‘dispersible 125’ Tablets (scored) with 100 mg levodopa + 25 mg benserazide	100
Madopar HBS Capsules with 100 mg levodopa + 25 mg benserazide	100

Not all presentations are available locally.

Medicine: keep out of reach of children

Current at May 2019

	F. Hoffmann-La Roche Ltd CH-4070 Basel, Switzerland
---	---